Navigation Links
The Combined Non-Small-Cell Lung Cancer Market of Argentina, Brazil and Mexico Will Grow at Six Percent Annually Through 2018
Date:12/10/2013

BURLINGTON, Mass., Dec. 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2013 to 2018, the non-small-cell lung cancer (NSCLC) market in Argentina, Brazil and Mexico will increase at an annual rate of six percent, reaching $495 million in 2018.

The Emerging Markets report, Non-Small-Cell Lung Cancer in Argentina, Brazil, and Mexico, also finds that changes in medical practice and reimbursement and the resulting continued uptake of targeted therapies will drive growth in this market. The market will also be sustained by a growing incident population and by the launch of 11 new branded therapies, despite limitations imposed on drug cancer coverage within the public sector.

Between 2013 and 2018, 11 novel branded NSCLC therapies will launch in Argentina, Brazil, and Mexico--Pfizer's crizotinib (which launched in Argentina and Mexico in March 2013 under brand name Xalkori), Celgene's nanoparticle paclitaxel, Boehringer Ingelheim's afatinib, Pfizer's dacomitinib, Novartis's ceritinib, Boehringer Ingelheim's nintedanib, Bristol-Myers Squibb's nivolumab, Roche's onartuzumab, Pfizer's dacomitinib, Eli Lilly's necitumumab, Eisai's eribulin and Merck & Co's MK-3475. Although the number of patients treated with these agents will be smaller compared to the world's major markets, the combined sales will comprise 16 percent of the total NSCLC market in 2018, owing to their high price.

The report, which includes primary research with Argentine, Brazilian and Mexican oncologists, also finds that the number of incident cases of NSCLC across the three geographies will increase by 25 percent between 2013 and 2023, because of an expanding and aging population and the strong association between risk and age.

"Out of the three countries, Brazil is the largest and most populated, with the highest incident population of NSCLC; it boasts the highest total sales of NSCLC therapies. But Argentina, with its wealthy population and good access to targeted therapies, was the undisputed leader of brand sales across the three markets, claiming over a half of all the brand sales in 2013," said Decision Resources Analyst Natalia Reoutova, M.A., M.Sc. "However, as targeted therapies and new branded agents experience greater uptake in Brazil and Mexico, Argentina's share of brand therapies becomes more diluted by 2018."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Agnitio Sets Up Asia HQ in Shanghai and is the First to Bring the Combined Closed Loops of Marketing and E-Learning to the Pharmaceutical Industry
2. JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes
3. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
4. MR Solutions to Launch Two World Firsts in Pre Clinical Scanning at the World Molecular Imaging Conference in Savannah This Week - a Combined 3T, Cryogen Free MRI/PET and a 3T MRI/SPECT
5. The US Ear, Nose And Throat And Bronchoscopy Device Markets Will Reach A Combined Value Exceeding $715 Million In 2021
6. Surveyed Oncologists Indicate that the Use of Biomarker Testing is Increasing Rapidly in Non-Small-Cell Lung Cancer in China and South Korea
7. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
8. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
9. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
10. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... -- In a startling report released today, National Safety Council ... comprehensive, proven plan to eliminate prescription opioid overdoses. Prescription ... are tackling the worst drug crisis in recorded U.S. history, assigned ... Kentucky , New Mexico , ... 28 failing states, three – Michigan , ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):